Tenofovir Df + Emtricitabine + Rilpivirine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: TDF – 300 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg
Reference Brands: Complera(US); Eviplera(EU)
Category: Anti Viral
Tenofovir DF + Emtricitabine + Rilpivirine, sold as Complera (US) and Eviplera (EU), is a once-daily HIV-1 treatment combining three antiretrovirals in one tablet. It’s FDA and EMA approved and must be taken with food.
Product Description:
Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Rilpivirine is a once-daily, fixed-dose combination used for the treatment of HIV-1 infection in treatment-naïve adults and adolescents. Marketed under the brand names Complera (US) and Eviplera (EU), it combines three powerful antiretroviral agents: TDF (a nucleotide reverse transcriptase inhibitor), Emtricitabine (an NRTI), and Rilpivirine (a non-nucleoside reverse transcriptase inhibitor). This single-tablet regimen simplifies HIV treatment, enhances patient adherence, and effectively suppresses viral load. Approved by the FDA and EMA, it is recommended for patients without resistance to any of its components and should be taken with a meal for optimal absorption.
Tenofovir Df + Emtricitabine + Rilpivirine — third party manufacturing & bulk supply
Tenofovir Df + Emtricitabine + Rilpivirine is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Tenofovir Df + Emtricitabine + Rilpivirine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Tenofovir Df + Emtricitabine + Rilpiviri... →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Tenofovir disoproxil fumarate, emtricitabine, and rilpivirine are used together as a complete regimen for the treatment of HIV-1 infection. This combination helps reduce viral load, increase CD4 cell counts, and prevent the progression of HIV when taken consistently. It is generally prescribed for treatment-naïve patients with stable viral levels and no resistance.
It is made from three antiretroviral agents: Tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor; Emtricitabine, a nucleoside reverse transcriptase inhibitor; and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Together, these ingredients block viral replication at multiple stages.
Its commonly known trade name is Complera in the USA and Eviplera in the EU and UK.
This combination is originally manufactured by Gilead Sciences in partnership with Janssen Pharmaceuticals for the rilpivirine component.
The generic name is Tenofovir disoproxil fumarate + Emtricitabine + Rilpivirine.
Brand names include Complera (USA) and Eviplera (EU/UK).
It is primarily manufactured in the USA and Europe by Gilead Sciences, with additional licensed generic manufacturing in India by several approved pharmaceutical companies.
Related Products
Brincidofovir
Strength:
100 mg, 10 mg/ml
Form: Tablets / Oral suspension
Reference Brands: Tembexa (USA/EU)
View Details
Lenacapavir
Strength:
300 mg, 463.5 mg/1.5 mL
Form: Tablet / Injection
Reference Brands: Yeztugo (USA), Sunlenca (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
